Manages exogenous obesity. ANDA 203436, held by Kvk Tech Inc. Phentermine Hydrochloride.
As of Nov 16, 2026, ANDA 203436 (Phentermine Hydrochloride), held by Kvk Tech Inc, was first approved by FDA on Mar 17, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Phentermine hydrochloride tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity in patients with an initial body mass index greater than or equal to 30 kg/m 2, or greater than or equal to 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 17, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phentermine Hydrochloride8MG · tablet;oral | Phentermine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters